ticlopidine has been researched along with Ischemic Attack, Transient in 256 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rationale and aim Little is known about the safety and efficacy of the combination of ticagrelor and aspirin in acute ischemic stroke." | 9.24 | Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. ( Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X, 2017) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 9.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 9.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 9.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 9.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 9.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 9.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.16 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 9.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 9.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 9.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication." | 9.06 | Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 8.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial." | 8.95 | Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. ( Chen, W; Han, Y; Huang, L; Johnston, SC; Li, X; Liu, L; Pan, Y; Wang, G; Wang, Y; Xu, Y; Yang, Q; Yi, X; Zhang, Q; Zhao, X, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 8.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 8.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Literature is scarce regarding the use of clopidogrel during pregnancy and the potential hazard to maternal and fetal health." | 8.90 | Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review. ( Cuesta-Fernandez, A; Kayaleh, OR; Reilly, CR, 2014) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 8.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 7.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients." | 7.88 | Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 7.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| "The objective of this study was to compare nonresponders (NR) and responders (R) to clopidogrel with respect to presence of microvascular and macrovascular pathology in a cohort of patients with recent minor ischemic stroke (IS) or transient ischemic attack (TIA)." | 7.81 | Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( Gigante, B; Höeg Dembrower, K; Jörneskog, G; Laska, AC; Laurencikas, E; Lundström, A; von Arbin, M; Wallén, H, 2015) |
| "The relation between high on-treatment platelet reactivity (HPR), and the level of glucose intolerance and insulin resistance (IR) was studied in clopidogrel-treated patients with minor ischemic stroke or TIA." | 7.80 | Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. ( Jörneskog, G; Laska, AC; Lundström, A; Von Arbin, M; Wallén, H, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 7.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 7.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 7.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 7.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 7.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug." | 7.69 | Delayed neutropenia with ticlopidine. ( Farver, DK; Hansen, LA, 1994) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 6.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 6.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 5.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rationale and aim Little is known about the safety and efficacy of the combination of ticagrelor and aspirin in acute ischemic stroke." | 5.24 | Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. ( Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X, 2017) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| "Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA)." | 5.22 | The role of ( Bath, PM; Leach, M; McDermott, JH; Newman, WG; Sen, D; Smith, CJ, 2022) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 5.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "Dual clopidogrel-aspirin therapy was associated with a marked reduction in new strokes compared with the therapy of aspirin alone in patients with normal renal function (hazard ratio, 0." | 5.22 | Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Wu, Y; Zhao, X; Zhou, Y, 2016) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone." | 5.20 | Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination." | 5.20 | Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. ( Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA." | 5.20 | Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. ( Fang, J; Hu, B; Johnston, SC; Li, H; Liu, L; Meng, X; Wang, A; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Zhao, X, 2015) |
| "To study whether Clopidogrel-Aspirin combined treatment for high risk transient ischaemic attack (TIA) or minor stroke results in increased number of lesions associated with anti-thrombotic cerebral haemorrhage or cerebral micro-bleeds (CMB) than aspirin alone treatment." | 5.20 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. ( Wang, P; Wang, Y; Wang, Z; Xin, H; Xu, C, 2015) |
| "We examined the efficacy and safety of dual antiplatelets in patients with transient ischemic attack or minor stroke, defined as National Institute of Health Stroke Scale scores 0-3, in a subgroup analysis of Clopidogrel plus aspirin versus Aspirin alone for Reducing embolization in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR) study." | 5.19 | Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study. ( Chen, C; Fu, J; Han, Z; Huang, Y; Lau, AY; Leung, TW; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2014) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 5.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "The aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone." | 5.17 | Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. ( Barsan, W; Battenhouse, H; Conwit, R; Dillon, C; Easton, JD; Elm, J; Farrant, M; Johnston, SC; Lindblad, A; Morgenstern, L; Palesch, Y; Poisson, SN, 2013) |
| " Patients were assessed at baseline [≤ 4 weeks of transient ischaemic attack (TIA) or ischaemic stroke], and at 14 days and ≥ 90 days after changing treatment from (i) no medication to aspirin monotherapy (N = 26) or (ii) aspirin to clopidogrel monotherapy (N = 22)." | 5.17 | High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study. ( Collins, DR; Coughlan, T; Egan, B; Feeley, TM; Kinsella, JA; McCabe, DJ; Murphy, RP; O'Neill, D; Tierney, S; Tobin, WO, 2013) |
| "In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291)." | 5.17 | Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. ( Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L, 2013) |
| "We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.16 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012) |
| "The clopidogrel plus aspirin for infarction reduction in acute stroke or transient ischaemic attack patients with large artery stenosis and microembolic signals (CLAIR) trial was a randomised, open-label, blinded-endpoint trial." | 5.14 | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. ( Chang, HM; Chen, C; Chollate, P; Fu, J; Han, Z; Hao, Q; Huang, YN; Koh, A; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2010) |
| "The study will randomize 5,100 Chinese patients with acute TIA or minor stroke to receive a 3-month regimen of clopidogrel initiated with a loading dose of 300 mg followed by 75 mg/d, combined with aspirin 75 mg/d during the first 21 days, or a 3-month regimen of aspirin 75 mg/d alone." | 5.14 | Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. ( Johnston, SC; Wang, Y, 2010) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Immediately after TIA or minor stroke, patients are at high risk of stroke, which might be reduced by using clopidogrel in addition to aspirin." | 5.12 | Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. ( Buchan, AM; Demchuk, AM; Eliasziw, M; Hill, MD; Kennedy, J; Ryckborst, KJ, 2007) |
| "The CAPRIE study showed the superiority of clopidogrel over acetylsalicylic acid (ASA) for reducing the combined risk of major atherothrombotic events in patients with recent myocardial infarction (MI), recent ischaemic stroke (IS) or established peripheral arterial disease." | 5.11 | Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. ( Bogousslavsky, J; Brass, LM; Cimminiello, C; Csiba, L; Diener, HC; Kaste, M; Leys, D; Matias-Guiu, J; Rupprecht, HJ, 2004) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 5.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 5.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication." | 5.06 | Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 4.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial." | 4.95 | Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. ( Chen, W; Han, Y; Huang, L; Johnston, SC; Li, X; Liu, L; Pan, Y; Wang, G; Wang, Y; Xu, Y; Yang, Q; Yi, X; Zhang, Q; Zhao, X, 2017) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 4.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 4.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0." | 4.90 | Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014) |
| "Literature is scarce regarding the use of clopidogrel during pregnancy and the potential hazard to maternal and fetal health." | 4.90 | Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review. ( Cuesta-Fernandez, A; Kayaleh, OR; Reilly, CR, 2014) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 4.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| "Low dose aspirin is effective in secondary stroke prevention." | 4.84 | Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. ( Kirshner, HS, 2007) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| "Aspirin is the treatment of first choice for long-term secondary prevention of vascular events in patients with confirmed non-cardioembolic ischaemic stroke or TIA." | 4.80 | Prevention of ischaemic stroke--antiplatelets. ( Brown, MM; McCabe, DJ, 2000) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| "The CHANCE-2 study compared 3 weeks of aspirin-ticagrelor to aspirin-clopidogrel in CYP2C19 loss-of-function (LOF) allele carriers following a transient ischemic attack (TIA)/minor stroke and demonstrated a modestly lower risk of stroke recurrence with aspirin-ticagrelor." | 4.31 | Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective. ( Demchuk, AM; Jahn, B; Menon, BK; Micieli, A; Siebert, U; Singh, N, 2023) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "The relationship of CYP2C19 genotype and clinical efficacy in stroke or transient ischemic attack (TIA) patients treated with clopidogrel monotherapy or clopidogrel plus aspirin remains unknown." | 3.88 | Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis. ( Cui, M; Gu, ZC; Li, WY; Pan, MM; Yao, JC, 2018) |
| "Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients." | 3.88 | Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018) |
| "From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel." | 3.85 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 3.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| "Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke." | 3.85 | Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017) |
| "The objective of this study was to compare nonresponders (NR) and responders (R) to clopidogrel with respect to presence of microvascular and macrovascular pathology in a cohort of patients with recent minor ischemic stroke (IS) or transient ischemic attack (TIA)." | 3.81 | Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( Gigante, B; Höeg Dembrower, K; Jörneskog, G; Laska, AC; Laurencikas, E; Lundström, A; von Arbin, M; Wallén, H, 2015) |
| "The relation between high on-treatment platelet reactivity (HPR), and the level of glucose intolerance and insulin resistance (IR) was studied in clopidogrel-treated patients with minor ischemic stroke or TIA." | 3.80 | Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. ( Jörneskog, G; Laska, AC; Lundström, A; Von Arbin, M; Wallén, H, 2014) |
| "A retrospective review of all patients with stroke and transient ischemic attack (TIA) tested for the clopidogrel CYP2C19 genotype was performed, with a collection of data including race/ethnicity, CYP2C19 status, and the presence of recurrent vascular events." | 3.80 | Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events. ( Barazangi, N; Chen, C; Jaramillo, V; Rose, J; Spokoyny, I; Tong, D; Wong, C, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| " Platelet reactivity was assessed in 18 patients with ischemic stroke/transient ischemic attack (TIA) 7 days (D7) and 90 days (D90) after prescription of clopidogrel, using four methods: light transmission aggregometry with 5 μmol/l ADP (LTA-ADP), vasodilator-stimulated phosphoprotein (VASP), Verify Now P2Y12 and platelet function analyzer (PFA) P2Y." | 3.80 | High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests. ( Arroyo, AB; Bernal, A; Guiú, IS; Iniesta, JA; Jover, E; Lozano, ML; Martínez, C; Rivera, J; Rodríguez, JM; Vicente, V, 2014) |
| "Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown." | 3.80 | Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke. ( Johnston, SC; Liu, G; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Zhao, K; Zhao, X, 2014) |
| "In patients with ischemic stroke or transient ischemic attack, 43% (n=128) and 35% (n=54) were nonresponders to aspirin and clopidogrel, respectively." | 3.78 | Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. ( Bakdash, S; Bhatt, DL; Depta, JP; Fowler, J; Katzan, I; Kottke-Marchant, K; Novak, E, 2012) |
| "To examine healthcare costs among patients hospitalized for transient ischemic attack or ischemic stroke (TIA/stroke) and prescribed aspirin plus extended-release dipyridamole (ASA-ERDP) or clopidogrel (CLOPID) within 30 days post-discharge using a retrospective claims database from a large US managed care organization." | 3.78 | One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. ( Burton, TM; Lacey, M; Lang, K; Liu, F; Monsalvo, ML; Sander, S; Yu, Y, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 3.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "Patients who have had a recent transient ischemic attack (TIA) are at high risk for subsequent stroke." | 3.77 | Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly. ( Adams, HP; Gordon, DL, 1991) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 3.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 3.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack." | 3.74 | Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack. ( Hills, NK; Johnston, SC, 2008) |
| "The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease." | 3.73 | Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006) |
| " The patient evolved with neutropenia induced by ticlopidine after 10 days of treatment." | 3.71 | Fibroelastoma of the mitral valve as a cause of transient ischemic stroke. ( Alessi, A; Bertolin Précoma, D; Fontoura, D; Gomes de Carvalho, R; Oliveira, LR; Zanis Neto, J; Zapparoli, M, 2001) |
| "Within a cross-sectional study, nested in a cohort we identified 931 patients with a recent ischemic stroke or TIA who were discharged with OAC or with one of the antiplatelet medications aspirin, clopidogrel, or the combination of aspirin and extended-release dipyridamole." | 3.71 | Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry. ( Lalouschek, W; Lang, W; Müllner, M, 2001) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug." | 3.69 | Delayed neutropenia with ticlopidine. ( Farver, DK; Hansen, LA, 1994) |
| "The study aimed to investigate the impact of clopidogrel combined with proton pump inhibitors (PPI) pantoprazole treatment on the prognosis of patients with transient ischemic attack (TIA)." | 2.84 | Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack. ( Lu, M, 2017) |
| "The incidences of transient ischemic attack, stroke, or death at up to 30 days after CAS in the high-OTR patients were similar between groups 1 and 2 (P = ." | 2.79 | Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting. ( Cayuela, A; González, A; Gonzalez-Marcos, JR; Mayol, A; Moniche, F; Montaner, J, 2014) |
| "In one patient a transient ischemic attack occurred." | 2.78 | High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial. ( Ackerstaff, RG; Breet, NJ; De Vries, JP; Deneer, VH; Elsenberg, EH; Hackeng, CM; Kelder, JC; Schonewille, WJ; Suttorp, MJ; Ten Berg, JM; Tromp, SC; Van Der Heyden, J; Van Neerven, D; Van Werkum, J; Vos, JA; Wolters, F, 2013) |
| "A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events." | 2.77 | Closure or medical therapy for cryptogenic stroke with patent foramen ovale. ( Adams, H; Albers, GW; Felberg, R; Furlan, AJ; Herrmann, H; Kar, S; Landzberg, M; Massaro, J; Mauri, L; Raizner, A; Reisman, M; Wechsler, L, 2012) |
| " The number of patients with adverse events and bleeding complications, and their severity, were significantly greater in the triple therapy group (p<0." | 2.73 | A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. ( Bath, PM; England, T; Gray, LJ; Sare, GM; Sprigg, N; Willmot, MR; Zhao, L, 2008) |
| "In these patients with type 2 diabetes and a history of TIA, patterns of platelet inhibition differed significantly according to whether treatment was with ER-DP+ASA or clopidogrel with or without ASA." | 2.73 | Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b ( Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL, 2008) |
| "The subjects were 75 patients with cerebral ischemia and 26 control subjects." | 2.67 | Shear-induced platelet aggregation in cerebral ischemia. ( Fukuyama, M; Handa, M; Ikeda, Y; Itagaki, I; Maruyama, S; Uchiyama, S; Yamazaki, M, 1994) |
| "Ticlopidine was more effective than aspirin in both sexes." | 2.66 | A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. ( Adams, HP; Anderson, S; Easton, JD; Hass, WK; Kamm, B; Molony, BA; Pryse-Phillips, W, 1989) |
| " The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk." | 2.55 | Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017) |
| " Although administration of antiplatelet agents has been confirmed to be one of the major approaches for secondary prevention of noncardioembolic stroke, the short-term or long-term use of aspirin plus clopidogrel for secondary stroke prevention remains to be controversial." | 2.52 | Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention. ( Chen, W; Wang, Y, 2015) |
| "These events, previously called apoplexy, are now called strokes." | 2.50 | Stroke: transient ischemic attack. ( Silver, B; Wulf Silver, R, 2014) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin has been shown to reduce the risk of recurrent strokes, and the combination of aspirin and dipyridamole has repeatedly been shown to outperform aspirin alone." | 2.46 | Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review. ( Fung, K; Simmons, BB; Yeo, A, 2010) |
| "In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours." | 2.46 | [New clinical concept and therapeutic strategy for TIA]. ( Urabe, T, 2010) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Patients who have transient ischemic attack (TIA) or ischemic stroke are at a high risk of having a first or recurrent stroke." | 2.44 | Antiplatelet agents and randomized trials. ( Diener, HC, 2007) |
| "The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week." | 2.43 | Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005) |
| "Six years later after a left cerebral transient ischemic attack aspirin was replaced by ticlopidine." | 2.41 | [Cholestatic hepatitis as a rare side effect of therapy with ticlopidine]. ( Auer, J; Berent, R; Haidenthaler, A; Hinterholzer, G; Höbling, W; Knoflach, P, 2000) |
| "Ticlopidine is a new antiplatelet agent with a distinct mechanism of action." | 2.38 | Ticlopidine and antiplatelet therapy. ( Flores-Runk, P; Raasch, RH, 1993) |
| "Strokes due to carotid artery stenosis differ in outcome from those due to cardiac embolism; the most benign group is that of lacunar strokes." | 2.38 | Outcome of transient ischaemic attacks and stroke. ( Norris, JW, 1991) |
| "Ticlopidine is a new prototype antiplatelet drug chemically unrelated to currently available agents." | 2.38 | Ticlopidine: a new antiplatelet agent for cerebrovascular disease. ( Fagan, SC; Miller, AJ; Robert, S, 1991) |
| "Hemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication." | 1.46 | Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. ( Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M, 2017) |
| "All the patients presented with carotid artery stenosis >70% (North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria), which was symptomatic in 42 patients (transient ischemic attack, n = 32; minor stroke, n = 10) and asymptomatic in 146." | 1.46 | Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study. ( Calio', FG; Illuminati, G; Masci, F; Pizzardi, G; Ricco, JB; Schneider, F, 2017) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 1.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Clinical question Following transient ischemic attack or acute minor stroke, does the combination of clopidogrel and aspirin reduce the risk of stroke greater than aspirin alone? Article chosen Wang Y, Wang Y, Zhao X, et al." | 1.42 | Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transient ischemic attack or acute minor stroke. ( Lang, E; Seadon, S, 2015) |
| "Treatment of intracranial fusiform aneurysms is complex and controversial, and is associated with high morbidity and mortality rates." | 1.39 | Using Leo Plus stent as flow diverter and endoluminal remodeling in endovascular treatment of intracranial fusiform aneurysms. ( Ageitos, M; Arias-Rivas, S; Blanco, M; Castiñeira-Mourenza, JA; Masso, A; Pumar, JM; Rodríguez-Yáñez, M; Vazquez-Herrero, F, 2013) |
| "Of a total of 4905 (transient ischemic attack/ischemic stroke, and ocular events) patients, 115 symptomatic patients underwent CEA, 42% within 14 days of the index event and 99% within 14 days of surgical referral." | 1.39 | Urgent best medical therapy may obviate the need for urgent surgery in patients with symptomatic carotid stenosis. ( Ellemann, K; Hjerpsted, U; Owen-Falkenberg, A; Rai, A; Shahidi, S, 2013) |
| "Intracranial arterial stenosis (IAS) is thought to be responsible for 8% of all ischemic stroke subtypes." | 1.37 | The role of transcranial Doppler embolic monitoring in the management of intracranial arterial stenosis. ( Derksen, C; Khan, K; Saqqur, M; Sebastian, J, 2011) |
| "Ischemic stroke was reported in 57." | 1.35 | [Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists]. ( Diehm, C; Köfüncü, E; Pittrow, D; Sander, D; Schwertfeger, M, 2008) |
| "We report a patient who presented with transient ischemic attack (TIA) associated with stenosis of the accessory MCA ostium." | 1.35 | Transient ischemic attack associated with stenosis of accessory middle cerebral artery: a case report. ( Gao, F; Jiang, WJ, 2009) |
| "Ticlopidine was then started." | 1.35 | Agenesis of the right internal carotid artery and Klippel-Feil syndrome: case report. ( Arpaia, G; Beretta, S; Braga, M; Canovaro, P; Crespi, V; Ferrarini, M; Pederzoli, M, 2009) |
| "Transient ischemic attack is one of the most common causes of transient neurologic deficit." | 1.35 | Severe anemia associated with transient ischemic attacks involving vertebrobasilar circulation. ( Chen, IC; Hsiao, CT; Hsiao, KY; Lin, LJ; Shiao, CJ, 2008) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period." | 1.33 | Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. ( Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005) |
| "Patients suffering from a transient ischemic attack (TIA) or ischemic stroke are at high risk of a recurrent stroke." | 1.32 | [Secondary prevention of stroke with antiplatelet drugs]. ( Diener, HC, 2004) |
| "Unfortunately, VBA transient ischemic attacks (TIAs) herald a lethal or devastating event within 5 years in 25 to 30% of patients." | 1.31 | Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience. ( Barr, JD; Furlan, AJ; Katzan, I; Krieger, D; Markarian, GZ; Masaryk, TJ; Perl, J; Rasmussen, PA; Sila, C, 2000) |
| "Ticlopidine treatment was stopped, and a prolonged course of prednisone was necessary to treat the pulmonary and intestinal symptoms." | 1.31 | Ticlopidine-induced interstitial pulmonary disease: a case report. ( Cornella, F; Kaeser, P; Persoz, CF; Rochat, T, 2001) |
| "Ticlopidine has been reported as causing neutropenia and isolated thrombocytopenia." | 1.29 | Thrombotic thrombocytopenic purpura associated with ticlopidine. ( Chin-Yee, IH; Kovacs, MJ; Soong, PY, 1993) |
| "A trial was performed on thirty-two patients with cerebrovascular disease (transient ischaemic attack and stroke) to assess the effect of ticlopidine, a new inhibitor of platelet aggregation, on some platelet functions and coagulation, and its safety in long-term use (6 months)." | 1.27 | Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease. ( Carfagna, S; Carrieri, P; Fioretti, A; Indaco, A; Orefice, G, 1984) |
| "A patient is described in whom transient ischemic attacks (TIA) had some features - namely the presence of headache and the progressive onset of symptoms - unusual for an embolic phenomenon but suggestive of a migrainous event." | 1.26 | [Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)]. ( Bousser, J; Bousser, MG; Conard, J; Lecrubier, C, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (3.91) | 18.7374 |
| 1990's | 31 (12.11) | 18.2507 |
| 2000's | 78 (30.47) | 29.6817 |
| 2010's | 132 (51.56) | 24.3611 |
| 2020's | 5 (1.95) | 2.80 |
| Authors | Studies |
|---|---|
| Micieli, A | 1 |
| Singh, N | 1 |
| Jahn, B | 1 |
| Siebert, U | 1 |
| Menon, BK | 1 |
| Demchuk, AM | 3 |
| Wang, X | 3 |
| Zhu, Q | 1 |
| Wu, Y | 2 |
| Li, H | 9 |
| Deng, X | 1 |
| Cheng, J | 1 |
| Zhang, Z | 1 |
| Ma, Y | 1 |
| Shi, T | 1 |
| McDermott, JH | 1 |
| Leach, M | 1 |
| Sen, D | 1 |
| Smith, CJ | 1 |
| Newman, WG | 1 |
| Bath, PM | 4 |
| Pan, YS | 1 |
| Wang, YJ | 1 |
| Cole, JW | 1 |
| Hilkens, NA | 1 |
| Algra, A | 2 |
| Diener, HC | 14 |
| Csiba, L | 2 |
| Hacke, W | 3 |
| Kappelle, LJ | 1 |
| Koudstaal, PJ | 1 |
| Leys, D | 3 |
| Mas, JL | 3 |
| Sacco, RL | 2 |
| Greving, JP | 1 |
| Wang, Y | 37 |
| Lin, Y | 3 |
| Meng, X | 12 |
| Chen, W | 4 |
| Chen, G | 1 |
| Wang, Z | 3 |
| Wu, J | 1 |
| Wang, D | 10 |
| Li, J | 5 |
| Cao, Y | 3 |
| Xu, Y | 2 |
| Zhang, G | 1 |
| Li, X | 2 |
| Pan, Y | 10 |
| Liu, L | 16 |
| Zhao, X | 16 |
| Rao, Z | 2 |
| Zheng, H | 3 |
| Wang, F | 2 |
| Wang, A | 9 |
| Dong, K | 2 |
| Rodés-Cabau, J | 1 |
| Masson, JB | 1 |
| Welsh, RC | 1 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 1 |
| Al-Qoofi, F | 1 |
| Généreux, P | 1 |
| Maluenda, G | 1 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Arous, S | 1 |
| Haboub, M | 1 |
| El Ghali Benouna, M | 1 |
| Bentaoune, T | 1 |
| Habbal, R | 1 |
| Lu, M | 1 |
| Lee, M | 2 |
| Saver, JL | 2 |
| Hong, KS | 2 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Ovbiagele, B | 2 |
| Zhang, J | 2 |
| Sun, H | 1 |
| Ming, T | 1 |
| Liu, X | 1 |
| Cong, Y | 1 |
| Li, F | 1 |
| Li, Z | 2 |
| Oza, R | 1 |
| Rundell, K | 1 |
| Garcellano, M | 1 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Beridze, M | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| Duley, L | 1 |
| England, TJ | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| James, M | 1 |
| Krishnan, K | 1 |
| Markus, HS | 4 |
| Montgomery, AA | 1 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Sprigg, N | 2 |
| Johnston, SC | 19 |
| Easton, JD | 7 |
| Farrant, M | 2 |
| Barsan, W | 2 |
| Conwit, RA | 1 |
| Elm, JJ | 1 |
| Kim, AS | 2 |
| Lindblad, AS | 1 |
| Palesch, YY | 1 |
| Ding, L | 1 |
| Peng, B | 1 |
| Yao, JC | 1 |
| Cui, M | 1 |
| Pan, MM | 1 |
| Gu, ZC | 1 |
| Li, WY | 1 |
| Rath, CL | 1 |
| Jørgensen, NR | 1 |
| Wienecke, T | 1 |
| Borchard-Tuch, C | 1 |
| Lau, AY | 2 |
| Zhao, Y | 2 |
| Chen, C | 4 |
| Leung, TW | 2 |
| Fu, J | 2 |
| Huang, Y | 2 |
| Suwanwela, NC | 2 |
| Han, Z | 2 |
| Tan, KS | 2 |
| Ratanakorn, D | 2 |
| Wong, KS | 4 |
| Lundström, A | 2 |
| Laska, AC | 2 |
| Von Arbin, M | 2 |
| Jörneskog, G | 2 |
| Wallén, H | 2 |
| Pumar, JM | 1 |
| Arias-Rivas, S | 1 |
| Rodríguez-Yáñez, M | 1 |
| Blanco, M | 1 |
| Ageitos, M | 1 |
| Vazquez-Herrero, F | 1 |
| Castiñeira-Mourenza, JA | 1 |
| Masso, A | 1 |
| Kono, K | 1 |
| Shintani, A | 1 |
| Yoshimura, R | 1 |
| Okada, H | 1 |
| Tanaka, Y | 1 |
| Fujimoto, T | 1 |
| Tomura, N | 1 |
| Terada, T | 1 |
| Shahidi, S | 2 |
| Owen-Falkenberg, A | 2 |
| Hjerpsted, U | 1 |
| Rai, A | 1 |
| Ellemann, K | 2 |
| Zuurbier, SM | 1 |
| Vermeer, SE | 1 |
| Hilkens, PH | 1 |
| Roos, YB | 1 |
| Rongen, GA | 1 |
| Hankey, GJ | 5 |
| Wang, C | 13 |
| Cui, L | 1 |
| Jia, J | 1 |
| Dong, Q | 1 |
| Xu, A | 1 |
| Zeng, J | 1 |
| Li, Y | 2 |
| Xia, H | 1 |
| Li, M | 3 |
| Li, JY | 1 |
| Xia, YP | 1 |
| Mao, L | 1 |
| Hu, B | 2 |
| Spokoyny, I | 1 |
| Barazangi, N | 1 |
| Jaramillo, V | 1 |
| Rose, J | 1 |
| Wong, C | 1 |
| Tong, D | 1 |
| Battenhouse, H | 1 |
| Conwit, R | 1 |
| Dillon, C | 1 |
| Elm, J | 1 |
| Lindblad, A | 1 |
| Morgenstern, L | 1 |
| Poisson, SN | 1 |
| Palesch, Y | 1 |
| Weimar, C | 2 |
| Gorelick, PB | 1 |
| Farooq, MU | 1 |
| Kakkos, SK | 1 |
| Tsolakis, IA | 1 |
| Sharma, M | 1 |
| Khandelwal, P | 1 |
| Jeong, YH | 1 |
| Hill, MD | 4 |
| Derdeyn, CP | 3 |
| Chimowitz, MI | 3 |
| Lynn, MJ | 3 |
| Fiorella, D | 3 |
| Turan, TN | 3 |
| Janis, LS | 3 |
| Montgomery, J | 2 |
| Nizam, A | 1 |
| Lane, BF | 3 |
| Lutsep, HL | 4 |
| Barnwell, SL | 2 |
| Waters, MF | 3 |
| Hoh, BL | 3 |
| Hourihane, JM | 2 |
| Levy, EI | 2 |
| Alexandrov, AV | 2 |
| Harrigan, MR | 2 |
| Chiu, D | 2 |
| Klucznik, RP | 2 |
| Clark, JM | 2 |
| McDougall, CG | 2 |
| Johnson, MD | 2 |
| Pride, GL | 2 |
| Lynch, JR | 1 |
| Zaidat, OO | 2 |
| Rumboldt, Z | 2 |
| Cloft, HJ | 2 |
| Gouya, G | 1 |
| Arrich, J | 1 |
| Wolzt, M | 1 |
| Huber, K | 1 |
| Verheugt, FW | 2 |
| Gurbel, PA | 2 |
| Pirker-Kees, A | 1 |
| Siller-Matula, JM | 1 |
| Gremmel, T | 1 |
| Koppensteiner, R | 1 |
| Ay, C | 1 |
| Panzer, S | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Nomani, F | 1 |
| Kamal, AK | 2 |
| Füessl, HS | 1 |
| González, A | 1 |
| Moniche, F | 1 |
| Cayuela, A | 1 |
| Gonzalez-Marcos, JR | 1 |
| Mayol, A | 1 |
| Montaner, J | 1 |
| Jover, E | 1 |
| Rodríguez, JM | 1 |
| Bernal, A | 1 |
| Arroyo, AB | 1 |
| Iniesta, JA | 1 |
| Guiú, IS | 1 |
| Martínez, C | 1 |
| Vicente, V | 1 |
| Lozano, ML | 1 |
| Rivera, J | 1 |
| Tobin, WO | 4 |
| Kinsella, JA | 4 |
| Kavanagh, GF | 2 |
| O'Donnell, JS | 2 |
| McGrath, RT | 1 |
| Coughlan, T | 4 |
| Collins, DR | 3 |
| O'Neill, D | 4 |
| Egan, B | 3 |
| Tierney, S | 3 |
| Feeley, TM | 3 |
| Murphy, RP | 4 |
| McCabe, DJ | 5 |
| Reilly, CR | 1 |
| Cuesta-Fernandez, A | 1 |
| Kayaleh, OR | 1 |
| Silver, B | 1 |
| Wulf Silver, R | 1 |
| Liu, G | 1 |
| Zhao, K | 1 |
| He, F | 1 |
| Xia, C | 1 |
| Zhang, JH | 1 |
| Li, XQ | 1 |
| Zhou, ZH | 1 |
| Li, FP | 1 |
| Li, W | 2 |
| Lv, Y | 1 |
| Chen, HS | 1 |
| Hu, Z | 1 |
| Yang, L | 1 |
| Zhang, Q | 2 |
| Zheng, M | 1 |
| Zhang, L | 1 |
| Shang, X | 1 |
| Yan, C | 1 |
| Szapáry, L | 1 |
| Koltai, K | 1 |
| Tibold, A | 1 |
| Fehér, A | 1 |
| Harang, G | 1 |
| Pusch, G | 1 |
| Fehér, G | 1 |
| Sandhu, RK | 1 |
| Hohnloser, SH | 1 |
| Pfeffer, MA | 1 |
| Yuan, F | 1 |
| Hart, RG | 1 |
| Yusuf, S | 1 |
| Connolly, SJ | 1 |
| McAlister, FA | 1 |
| Healey, JS | 1 |
| Lin, J | 4 |
| Jickling, GC | 1 |
| Liu, F | 2 |
| Tantry, US | 1 |
| Seadon, S | 1 |
| Lang, E | 1 |
| Alderazi, YJ | 1 |
| Batchelder, A | 1 |
| Hunter, J | 1 |
| Cairns, V | 1 |
| Sandford, R | 1 |
| Munshi, A | 1 |
| Naylor, AR | 1 |
| Xian, Y | 2 |
| Fang, J | 1 |
| Gigante, B | 1 |
| Höeg Dembrower, K | 1 |
| Laurencikas, E | 1 |
| Leng, X | 1 |
| Pu, Y | 1 |
| Jing, J | 3 |
| Zou, X | 1 |
| Soo, Y | 1 |
| Cotsonis, GA | 1 |
| Davis, KA | 1 |
| Miyares, MA | 1 |
| Dietrich, E | 1 |
| Xu, C | 1 |
| Wang, P | 1 |
| Xin, H | 1 |
| Gong, Y | 1 |
| McDonough, CW | 1 |
| Royster, AJ | 1 |
| Sheehan, TO | 1 |
| Burkley, B | 1 |
| Langaee, TY | 1 |
| Mocco, J | 1 |
| Zuckerman, SL | 1 |
| Mummareddy, N | 1 |
| Stephens, ML | 1 |
| Ingram, C | 1 |
| Shaffer, CM | 1 |
| Denny, JC | 1 |
| Brilliant, MH | 1 |
| Kitchner, TE | 1 |
| Linneman, JG | 1 |
| Roden, DM | 1 |
| Johnson, JA | 1 |
| Gottschalksen, B | 1 |
| Yang, C | 1 |
| Qian, J | 1 |
| Tang, X | 1 |
| Gao, P | 1 |
| Hu, Y | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Yang, X | 1 |
| Zhang, C | 1 |
| Ge, F | 1 |
| Lin, H | 2 |
| Liu, Y | 1 |
| Guo, R | 1 |
| Ruan, Z | 1 |
| Chang, T | 1 |
| Xu, J | 1 |
| Buck, J | 1 |
| Kaboli, P | 1 |
| Gage, BF | 1 |
| Cram, P | 1 |
| Vaughan Sarrazin, MS | 1 |
| Amarenco, P | 1 |
| Čulić, V | 1 |
| Landman, GW | 1 |
| Kleefstra, N | 1 |
| Zhou, Y | 1 |
| Yi, X | 1 |
| Han, Y | 1 |
| Yang, Q | 1 |
| Huang, L | 1 |
| Wang, G | 1 |
| Sawlani, NN | 1 |
| Harrington, RA | 1 |
| Stone, GW | 1 |
| Steg, PG | 1 |
| Gibson, CM | 1 |
| Hamm, CW | 1 |
| Price, MJ | 1 |
| Prats, J | 1 |
| Deliargyris, EN | 1 |
| Mahaffey, KW | 2 |
| White, HD | 1 |
| Bhatt, DL | 3 |
| Xu, H | 1 |
| Ping, Y | 1 |
| He, P | 1 |
| Dai, H | 1 |
| Sun, X | 1 |
| Tong, X | 1 |
| Lo, WT | 1 |
| Mo, D | 1 |
| Gao, F | 2 |
| Ma, N | 1 |
| Wang, B | 1 |
| Miao, Z | 1 |
| Illuminati, G | 1 |
| Schneider, F | 1 |
| Pizzardi, G | 1 |
| Masci, F | 1 |
| Calio', FG | 1 |
| Ricco, JB | 1 |
| Moris, D | 1 |
| Bakoyiannis, C | 1 |
| Avgerinos, E | 1 |
| Ou, L | 1 |
| Serebruany, VL | 2 |
| Alberts, MJ | 3 |
| Hanley, DF | 2 |
| Gray, LJ | 1 |
| England, T | 1 |
| Willmot, MR | 1 |
| Zhao, L | 1 |
| Sare, GM | 1 |
| Sander, D | 1 |
| Schwertfeger, M | 1 |
| Köfüncü, E | 1 |
| Diehm, C | 1 |
| Pittrow, D | 1 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Yu, SC | 1 |
| Lam, WW | 1 |
| Chan, AY | 1 |
| Wong, LK | 1 |
| Jiang, WJ | 1 |
| Biller, J | 1 |
| Braga, M | 1 |
| Pederzoli, M | 1 |
| Beretta, S | 1 |
| Ferrarini, M | 1 |
| Canovaro, P | 1 |
| Arpaia, G | 1 |
| Crespi, V | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Sebastian, J | 1 |
| Derksen, C | 1 |
| Khan, K | 1 |
| Saqqur, M | 1 |
| Albanese, A | 1 |
| Esposito, G | 1 |
| Puca, A | 1 |
| Tuttolomondo, A | 1 |
| Tirpakova, B | 1 |
| Di Giuda, D | 1 |
| Maira, G | 1 |
| Di Lazzaro, V | 1 |
| Simmons, BB | 1 |
| Yeo, A | 1 |
| Fung, K | 1 |
| Geraghty, OC | 2 |
| Kennedy, J | 2 |
| Chandratheva, A | 2 |
| Marquardt, L | 1 |
| Buchan, AM | 3 |
| Rothwell, PM | 3 |
| Chang, HM | 2 |
| Huang, YN | 1 |
| Chollate, P | 1 |
| Koh, A | 1 |
| Hao, Q | 1 |
| Kaste, M | 2 |
| Polydorou, AD | 1 |
| Megaloikonomos, P | 1 |
| Moutiris, JA | 1 |
| Polydorou, V | 1 |
| Antypa, E | 1 |
| Testembasi, E | 1 |
| Tziakouri, CH | 1 |
| Palatianos, G | 1 |
| Nikas, D | 1 |
| Bolos, K | 1 |
| Polydorou, A | 1 |
| Meves, SH | 1 |
| Overbeck, U | 1 |
| Kaiser, A | 1 |
| Krogias, C | 1 |
| Neubauer, H | 1 |
| Paul, NL | 1 |
| Feldman, MJ | 1 |
| Curinga, G | 1 |
| Milner, SM | 1 |
| Fischer, D | 1 |
| Haentjes, J | 1 |
| Klein, G | 1 |
| Schieffer, B | 1 |
| Drexler, H | 1 |
| Meyer, GP | 1 |
| Schaefer, A | 1 |
| Kral, M | 1 |
| Herzig, R | 1 |
| Sanak, D | 1 |
| Skoloudik, D | 1 |
| Vlachova, I | 1 |
| Bartkova, A | 1 |
| Hlustik, P | 1 |
| Kovacik, M | 1 |
| Kanovsky, P | 1 |
| Brennan, D | 1 |
| Mak, KH | 1 |
| Fox, KA | 1 |
| Topol, EJ | 1 |
| Charles, J | 1 |
| Miller, G | 1 |
| Meyers, JL | 1 |
| Davis, KL | 1 |
| Yu, YF | 1 |
| Weber, R | 1 |
| Röther, J | 1 |
| Guthrie, R | 1 |
| Vidal-Jordana, A | 1 |
| Barroeta-Espar, I | 1 |
| Sáinz Pelayo, MP | 1 |
| Mateo, J | 1 |
| Delgado-Mederos, R | 1 |
| Martí-Fàbregas, J | 1 |
| Squizzato, A | 1 |
| Romualdi, E | 1 |
| Dentali, F | 1 |
| Ageno, W | 1 |
| Chaturvedi, S | 1 |
| Bhattacharya, P | 1 |
| Torbey, MT | 1 |
| Urabe, T | 2 |
| Rosenberg, K | 1 |
| Aw, D | 1 |
| Sharma, JC | 1 |
| Khan, M | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Asil, T | 1 |
| Ir, N | 1 |
| Karaduman, F | 1 |
| Cagli, B | 1 |
| Tuncel, S | 1 |
| Furlan, AJ | 2 |
| Reisman, M | 1 |
| Massaro, J | 1 |
| Mauri, L | 1 |
| Adams, H | 1 |
| Albers, GW | 1 |
| Felberg, R | 1 |
| Herrmann, H | 1 |
| Kar, S | 1 |
| Landzberg, M | 1 |
| Raizner, A | 1 |
| Wechsler, L | 1 |
| James, SK | 2 |
| Storey, RF | 2 |
| Khurmi, NS | 1 |
| Husted, S | 2 |
| Keltai, M | 1 |
| Maya, J | 1 |
| Morais, J | 2 |
| Lopes, RD | 1 |
| Nicolau, JC | 2 |
| Pais, P | 1 |
| Raev, D | 1 |
| Lopez-Sendon, JL | 1 |
| Stevens, SR | 1 |
| Becker, RC | 1 |
| Depta, JP | 1 |
| Fowler, J | 1 |
| Novak, E | 1 |
| Katzan, I | 3 |
| Bakdash, S | 1 |
| Kottke-Marchant, K | 1 |
| Burton, TM | 1 |
| Lacey, M | 1 |
| Yu, Y | 1 |
| Monsalvo, ML | 1 |
| Lang, K | 1 |
| Sander, S | 1 |
| Rossen, JD | 1 |
| Chalouhi, N | 1 |
| Wassef, SN | 1 |
| Thomas, J | 1 |
| Abel, TJ | 1 |
| Jabbour, PM | 1 |
| Kung, DK | 1 |
| Hasan, DM | 1 |
| Cox, D | 1 |
| Collins, R | 1 |
| McGrath, RA | 1 |
| Biscaglia, S | 1 |
| Tebaldi, M | 1 |
| Vranckx, P | 1 |
| Campo, G | 1 |
| Valgimigli, M | 1 |
| Van Der Heyden, J | 1 |
| Van Werkum, J | 1 |
| Hackeng, CM | 1 |
| Kelder, JC | 1 |
| Breet, NJ | 1 |
| Deneer, VH | 1 |
| Ackerstaff, RG | 2 |
| Tromp, SC | 1 |
| De Vries, JP | 2 |
| Vos, JA | 1 |
| Suttorp, MJ | 1 |
| Elsenberg, EH | 1 |
| Van Neerven, D | 1 |
| Schonewille, WJ | 1 |
| Wolters, F | 1 |
| Ten Berg, JM | 1 |
| Kohli, P | 1 |
| Wallentin, L | 1 |
| Reyes, E | 1 |
| Horrow, J | 1 |
| Angiolillo, DJ | 1 |
| Ardissino, D | 1 |
| Maurer, G | 1 |
| Oto, A | 1 |
| Cannon, CP | 1 |
| Ito, E | 1 |
| Takahashi, A | 1 |
| Yamamoto, H | 1 |
| Kuzuhara, S | 1 |
| Uchiyama, S | 2 |
| Nakajima, M | 1 |
| Georgiadis, D | 1 |
| Michel, P | 1 |
| Bogousslavsky, J | 4 |
| Baumgartner, RW | 1 |
| Elkind, MS | 1 |
| Brass, LM | 1 |
| Cimminiello, C | 1 |
| Matias-Guiu, J | 1 |
| Rupprecht, HJ | 1 |
| Nácul, FE | 1 |
| de Moraes, E | 1 |
| Penido, C | 1 |
| Paiva, RB | 1 |
| Méier-Neto, JG | 1 |
| Moonis, M | 1 |
| Fisher, M | 1 |
| Moore, M | 1 |
| Power, M | 1 |
| Einecke, D | 1 |
| Frey, JL | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Weir, NU | 1 |
| Eikelboom, JW | 1 |
| Droste, DW | 1 |
| Kaps, M | 1 |
| Larrue, V | 1 |
| Lees, KR | 1 |
| Siebler, M | 2 |
| Ringelstein, EB | 1 |
| Biondi, A | 1 |
| Katz, JM | 1 |
| Vallabh, J | 1 |
| Segal, AZ | 1 |
| Gobin, YP | 1 |
| Gebel, JM | 1 |
| Fahey, CD | 1 |
| Bernstein, RA | 1 |
| Nitschmann, S | 1 |
| Hartung, HP | 1 |
| Boltuch, J | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Dick, P | 1 |
| Mlekusch, W | 1 |
| Schlager, O | 1 |
| Ahmadi, A | 1 |
| Minar, E | 1 |
| Schillinger, M | 1 |
| Bezerra, DC | 1 |
| Esagunde, RU | 1 |
| Lee, MP | 1 |
| Gan, HY | 1 |
| Wong, MC | 1 |
| Chen, CL | 1 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| Wallaschofski, H | 1 |
| Lohmann, T | 1 |
| Hild, E | 1 |
| Kobsar, A | 1 |
| Siegemund, A | 1 |
| Spilcke-Liss, E | 1 |
| Hentschel, B | 1 |
| Stumpf, C | 1 |
| Daniel, WG | 1 |
| Garlichs, CD | 1 |
| Eigenthaler, M | 1 |
| Cordonnier, C | 1 |
| Gorelick, P | 2 |
| Sechenova, O | 1 |
| Hennekens, CH | 1 |
| Sylaja, PN | 1 |
| Liao, JK | 1 |
| de Borst, GJ | 1 |
| Hilgevoord, AA | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Macdonald, S | 1 |
| Fintel, DJ | 1 |
| Kirshner, HS | 1 |
| Ryckborst, KJ | 1 |
| Eliasziw, M | 1 |
| Overgaard, K | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 1 |
| Weinberger, J | 1 |
| Müller-Schunk, S | 1 |
| Linn, J | 1 |
| Peters, N | 1 |
| Spannagl, M | 1 |
| Deisenberg, M | 1 |
| Brückmann, H | 1 |
| Mayer, TE | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Schwamm, LH | 1 |
| Hills, NK | 1 |
| Malinin, AI | 1 |
| Pokov, AN | 1 |
| Hsiao, KY | 1 |
| Hsiao, CT | 1 |
| Lin, LJ | 1 |
| Shiao, CJ | 1 |
| Chen, IC | 1 |
| Asensio Moreno, C | 1 |
| Arias Jiménez, JL | 1 |
| Aramburu Bodas, O | 1 |
| Ortega Calvo, M | 1 |
| Pérez Cano, R | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Boysen, G | 1 |
| Ono, H | 1 |
| Mizukami, M | 1 |
| Kitamura, K | 1 |
| Kikuchi, H | 1 |
| Tohgi, H | 2 |
| Gent, M | 1 |
| Ellis, D | 1 |
| Carrieri, P | 1 |
| Orefice, G | 1 |
| Fioretti, A | 1 |
| Indaco, A | 1 |
| Carfagna, S | 1 |
| Bousser, MG | 1 |
| Conard, J | 1 |
| Lecrubier, C | 1 |
| Bousser, J | 1 |
| Farver, DK | 1 |
| Hansen, LA | 1 |
| Iwamoto, T | 1 |
| Kubo, H | 1 |
| Takasaki, M | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Barnett, HJ | 1 |
| Feussner, JR | 1 |
| Komiya, T | 1 |
| Kudo, M | 1 |
| Mizuno, Y | 1 |
| Yamazaki, M | 1 |
| Maruyama, S | 1 |
| Handa, M | 1 |
| Ikeda, Y | 1 |
| Fukuyama, M | 1 |
| Itagaki, I | 1 |
| Weiller, C | 1 |
| Brey, RL | 1 |
| Oster, G | 1 |
| Huse, DM | 1 |
| Lacey, MJ | 1 |
| Epstein, AM | 1 |
| Macko, R | 1 |
| Kovacs, MJ | 1 |
| Soong, PY | 1 |
| Chin-Yee, IH | 1 |
| Flores-Runk, P | 1 |
| Raasch, RH | 1 |
| Nurhussein, MA | 1 |
| Bellavance, A | 1 |
| Rindone, JP | 1 |
| Bryan, G | 1 |
| Jimenez Moreno, FJ | 1 |
| Junquera Florez, F | 1 |
| Nuvias Casals, J | 1 |
| Castells Fuste, L | 1 |
| Gonzalez Fernandez, A | 1 |
| Catella-Lawson, F | 1 |
| FitzGerald, GA | 1 |
| Chesney, CM | 1 |
| Forbes, CD | 1 |
| Pizzulli, L | 1 |
| Lüderitz, B | 1 |
| Brigot, C | 1 |
| Courillon-Mallet, A | 1 |
| Roucayrol, AM | 1 |
| Cattan, D | 1 |
| Leavey, SF | 1 |
| Weinberg, J | 1 |
| Rasmussen, PA | 1 |
| Perl, J | 1 |
| Barr, JD | 1 |
| Markarian, GZ | 1 |
| Sila, C | 1 |
| Krieger, D | 1 |
| Masaryk, TJ | 1 |
| Sudlow, CL | 1 |
| Dunbabin, DW | 1 |
| Berent, R | 1 |
| Hinterholzer, G | 1 |
| Höbling, W | 1 |
| Auer, J | 1 |
| Haidenthaler, A | 1 |
| Knoflach, P | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Brown, MM | 1 |
| Persoz, CF | 1 |
| Cornella, F | 1 |
| Kaeser, P | 1 |
| Rochat, T | 1 |
| Alessi, A | 1 |
| Gomes de Carvalho, R | 1 |
| Bertolin Précoma, D | 1 |
| Fontoura, D | 1 |
| Oliveira, LR | 1 |
| Zanis Neto, J | 1 |
| Zapparoli, M | 1 |
| Lalouschek, W | 1 |
| Lang, W | 1 |
| Müllner, M | 1 |
| Shukla, V | 1 |
| Goertler, M | 1 |
| Blaser, T | 1 |
| Krueger, S | 1 |
| Hofmann, K | 1 |
| Baeumer, M | 1 |
| Wallesch, CW | 1 |
| Wilterdink, JL | 1 |
| Norris, JW | 1 |
| Adams, HP | 2 |
| Gordon, DL | 1 |
| Robert, S | 1 |
| Miller, AJ | 1 |
| Fagan, SC | 1 |
| Warlow, C | 1 |
| Janzon, L | 1 |
| Bergqvist, D | 1 |
| Boberg, J | 1 |
| Boberg, M | 1 |
| Eriksson, I | 1 |
| Lindgärde, F | 1 |
| Persson, G | 1 |
| Almgren, B | 1 |
| Fagher, B | 1 |
| Kjellström, T | 1 |
| Hass, WK | 1 |
| Pryse-Phillips, W | 1 |
| Molony, BA | 1 |
| Anderson, S | 1 |
| Kamm, B | 1 |
| Mirsen, TR | 1 |
| Hachinski, VC | 1 |
| Fujita, K | 1 |
| Yamashita, H | 1 |
| Masumura, M | 1 |
| Ehara, K | 1 |
| Tamaki, N | 1 |
| Matsumoto, S | 1 |
| Harker, LA | 1 |
| Murakami, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.[NCT02506140] | Phase 2/Phase 3 | 675 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-06-01 | Not yet recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314] | 144 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis[NCT00576693] | Phase 3 | 451 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Stroke Imaging Package Study of Intracranial Atherosclerosis[NCT03719820] | 550 participants (Anticipated) | Observational [Patient Registry] | 2018-11-14 | Recruiting | |||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| Evolocumab Added to Statin Therapy in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)---a Pilot Study[NCT05741086] | Phase 3 | 80 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | ||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Intracranial Stenting in Non-acute Symptomatic Ischemic Stroke: an Open-label, Randomised Controlled Trial[NCT05063630] | 300 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Wingspan One Year Vascular Imaging Events and Neurologic Outcomes (WOVEN)[NCT04221984] | 129 participants (Actual) | Observational [Patient Registry] | 2019-11-12 | Completed | |||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)[NCT00004732] | 2,502 participants (Actual) | Interventional | 2000-12-31 | Completed | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| The Effect of Early Administration of PCSK9 Inhibitor, Alirocumab to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid Profile, a Single Center Study, Registry Based, Pragmatic, Prospective Trial[NCT06083961] | Phase 4 | 200 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | ||
| A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism [NCT00201461] | Phase 2/Phase 3 | 900 participants (Anticipated) | Interventional | 2003-06-30 | Active, not recruiting | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Does the Magnitude of Platelet Inhibition Inversely Correlate With the Number of TCD-detected Microemboli in Asymptomatic Patients Undergoing Carotid Artery Stenting Prior to Cardiac Surgery Who Are Being Pre-treated With 300 mg or 600 mg Loading Dose of [NCT01146301] | Phase 4 | 0 participants | Interventional | 2008-03-31 | Completed | ||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)[NCT00109382] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2003-05-31 | Completed | ||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke[NCT00012454] | Phase 2 | 60 participants | Interventional | 2001-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up. (NCT00576693)
Timeframe: Mean length of follow-up was 2.4 years
| Intervention | participants (Number) |
|---|---|
| Intensive Medical Management Plus Stenting | 52 |
| Intensive Medical Management Alone | 34 |
The primary aim of CREST is to assess if the efficacy of CAS differs from that of CEA in preventing stroke, myocardial infarction and death during a 30-day peri-procedural period, or ipsilateral stroke over the follow-up period in patients with symptomatic (>=50%) or asymptomatic (>=60%) extracranial carotid stenosis. Four-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 30 days and 4 years
| Intervention | Percentage (Mean) |
|---|---|
| Carotid-Artery Stenting | 7.2 |
| Carotid Endarterectomy | 6.8 |
4-year follow-up, proportions reflecting the absolute efficacy of carotid-artery stenting (CAS) over that of carotid endarterectomy (CEA) were based on Kaplan-Meier survival estimates at the end of the 4 years. (NCT00004732)
Timeframe: 4 years
| Intervention | Percentage (Mean) | |
|---|---|---|
| Men | Women | |
| Carotid Endarterectomy | 6.8 | 6.7 |
| Carotid-Artery Stenting | 6.2 | 8.9 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
65 reviews available for ticlopidine and Ischemic Attack, Transient
| Article | Year |
|---|---|
The role of
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2022 |
[Optimal antiplatelet strategy in patients with high-risk transient ischemic attack and minor ischemic stroke].
Topics: Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticlopi | 2019 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat | 2017 |
Recurrent Ischemic Stroke: Strategies for Prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P | 2017 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
[Secondary prevention with clopidogrel after TIA or stroke].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; N | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie | 2014 |
Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review.
Topics: Adult; Clopidogrel; Delivery, Obstetric; Female; Humans; Infant, Newborn; Ischemic Attack, Transient | 2014 |
Stroke: transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance I | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Hemorrhag | 2015 |
Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic | 2015 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2016 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Topics: Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Databases, Factual; Genotype; Humans; Ischemic Attac | 2017 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
Topics: American Heart Association; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; I | 2010 |
Oral antiplatelet therapy in stroke prevention. Minireview.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Drug Combinations; Humans; Ischemic Attack | 2010 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop | 2011 |
Statins for acute ischemic stroke.
Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reduct | 2011 |
New insights in antiplatelet therapy for patients with ischemic stroke.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; I | 2011 |
[New clinical concept and therapeutic strategy for TIA].
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diffusion Magnetic Resonance Imaging; Humans; Ischemic Attac | 2010 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
[Treatment of acute stroke -- an overview].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Brain Edema; Case-Control Studies; Cereb | 2003 |
The role of warfarin and aspirin in secondary prevention of stroke.
Topics: Anticoagulants; Aspirin; Clopidogrel; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transie | 2004 |
Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Combinations; Human | 2003 |
The results of MATCH: light or heat?
Topics: Aspirin; Clopidogrel; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ischem | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Stroke prevention. MATCHing therapy to the patient with TIA.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2005 |
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2006 |
Current management of transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Endarterectomy, Carotid; Humans; Ischemic Attack, T | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
[What should be done after the first TIA?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopi | 2007 |
Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' resu
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Embolism, C | 2007 |
Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Family P | 2007 |
Antiplatelet agents and randomized trials.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; P | 2007 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
[Ticlopidine. Secondary prevention of ischemic cerebral infarct].
Topics: Adult; Aged; Cerebral Infarction; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female | 1993 |
Ticlopidine and antiplatelet therapy.
Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Interactions; Hum | 1993 |
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi | 1997 |
Antiplatelet drugs in secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Huma | 1998 |
Thrombotic thrombocytopenic purpura associated with ticlopidine therapy.
Topics: Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inh | 1997 |
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2000 |
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].
Topics: Aged; Atrial Fibrillation; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Cholestasis; Chro | 2000 |
Prevention of ischaemic stroke--antiplatelets.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Pl | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
Outcome of transient ischaemic attacks and stroke.
Topics: Aged; Carotid Stenosis; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Middle Aged; | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Ticlopidine: a new antiplatelet agent for cerebrovascular disease.
Topics: Cerebrovascular Disorders; Clinical Trials as Topic; Drug Interactions; Female; Humans; Ischemic Att | 1991 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Transient ischemic attacks and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Risk Factors; Ticlopidine | 1988 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
55 trials available for ticlopidine and Ischemic Attack, Transient
| Article | Year |
|---|---|
Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design.
Topics: Adenosine; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hetero | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Report: Impact of drug combination of clopidogrel and pantoprazole In the prognosis of patients with transient ischemic attack.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Chi-Square Distribution; China; Cl | 2017 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study.
Topics: Adult; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; I | 2014 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Double-Blind Method; Drug The | 2013 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting.
Topics: Aged; Angioplasty; Blood Platelets; Carotid Artery Diseases; Clopidogrel; Female; Humans; Ischemic A | 2014 |
Clopidogrel plus aspirin versus aspirin alone for preventing early neurological deterioration in patients with acute ischemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; M | 2015 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopid | 2015 |
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studie | 2015 |
Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy.
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ischemic | 2015 |
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination | 2015 |
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?
Topics: Angioplasty; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Constriction, Patholo | 2015 |
Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
Topics: Aged; Aspirin; Cerebral Cortex; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Female; | 2015 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Effect of Estimated Glomerular Filtration Rate Decline on the Efficacy and Safety of Clopidogrel With Aspirin in Minor Stroke or Transient Ischemic Attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events).
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Comorbidity; Drug Therapy, Combi | 2016 |
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin | 2017 |
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al | 2017 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Doubl | 2008 |
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Drug Tolerance; | 2008 |
Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Drug Therapy, Combina | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Humans; Intention to Treat Ana | 2010 |
Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Stenting versus aggressive medical therapy for intracranial arterial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Follow-Up St | 2011 |
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Co | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial | 2012 |
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Ischemic Attack, Tr | 2013 |
High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial.
Topics: Aged; Cardiac Surgical Procedures; Carotid Stenosis; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic A | 2013 |
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac | 2003 |
Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2004 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Drug Therapy, Combination; Femal | 2007 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-b
Topics: Adult; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Biomarkers; Clopidogrel; Diabetes Mell | 2008 |
Ticlopidine: quo vadis? Subarachnoid hemorrhage.
Topics: Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Humans; Intracranial Aneurysm; Ischem | 1984 |
The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; I | 1984 |
Canadian American ticlopidine study (cats) in thromboembolic stroke.
Topics: Anticoagulants; Clinical Trials as Topic; Follow-Up Studies; Humans; Intracranial Embolism and Throm | 1984 |
Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebral Infarction; Collagen; Drug Monitoring; Female; Follow | 1994 |
Shear-induced platelet aggregation in cerebral ischemia.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Brain Ischemia; Cerebral Infarction; | 1994 |
Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Fol | 1993 |
Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke.
Topics: Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Emb | 2002 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study.
Topics: Aged; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Intermittent Claudication; Ischem | 1990 |
A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
Topics: Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; M | 1989 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
[Pathophysiology and treatment of thrombosis. (2) The effect of ticlopidine on TIA compared with aspirin. A double-blind, 12-month and open 24-month follow-up study].
Topics: Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; Ischemic Attack, | 1987 |
139 other studies available for ticlopidine and Ischemic Attack, Transient
| Article | Year |
|---|---|
Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Topics: Aspirin; Canada; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Humans; Ischemic Atta | 2023 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
Topics: Clopidogrel; Humans; Ischemic Attack, Transient; Precision Medicine; Stroke; Ticlopidine | 2021 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem | 2017 |
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports.
Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Atta | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2017 |
Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genotype; Humans; Ischemi | 2018 |
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
Topics: Aged; Clopidogrel; Denmark; Drug Resistance; Female; Humans; Ischemic Attack, Transient; Male; Medic | 2018 |
[In process].
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhi | 2017 |
New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ischemic Attack, Trans | 2019 |
Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA.
Topics: Aged; Blood Glucose; Blood Platelets; Clopidogrel; Female; Glucose Intolerance; Humans; Insulin Resi | 2014 |
Using Leo Plus stent as flow diverter and endoluminal remodeling in endovascular treatment of intracranial fusiform aneurysms.
Topics: Adult; Aged; Anesthesia, General; Aneurysm; Angiography, Digital Subtraction; Aspirin; Blepharoptosi | 2013 |
Triple antiplatelet therapy with addition of cilostazol to aspirin and clopidogrel for Y-stent-assisted coil embolization of cerebral aneurysms.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2013 |
Urgent best medical therapy may obviate the need for urgent surgery in patients with symptomatic carotid stenosis.
Topics: Adult; Ambulatory Care; Carotid Stenosis; Clopidogrel; Disease Management; Drug Therapy, Combination | 2013 |
[Clopidogrel plus acetylsalicylic acid: a deadly combination].
Topics: Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Preventi | 2013 |
Dual antiplatelet therapy in acute transient ischemic attack and minor stroke.
Topics: Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stro | 2013 |
Early dual therapy for Chinese adults with TIA.
Topics: Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Humans; Intracranial Hemorrhages; Is | 2013 |
Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C19; Dru | 2014 |
Stroke: a new CHANCE for combination antiplatelet therapy?
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2014 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Clopidogrel with aspirin in minor stroke or transient ischemic attack.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
ACP Journal Club. Adding clopidogrel to aspirin after TIA or minor ischemic stroke reduced stroke without increasing bleeding.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Clopidogrel | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
LOAD: a pilot study of the safety of loading of aspirin & clopidogrel in acute ischaemic stroke and transient ischaemic attack. Is the loading dose of aspirin and clopidogrel a good alternative for patients with acute ischaemic stroke and TIA? How this wi
Topics: Aspirin; Brain Ischemia; Female; Humans; Ischemic Attack, Transient; Male; Ticlopidine | 2013 |
[Not Available].
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2013 |
High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cell Adhesion Molecules; Cells, Cul | 2014 |
Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Enzyme-Linked Immunosorbent Assay; Female; Humans; | 2014 |
Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
Topics: Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; H | 2014 |
Does clopidogrel with aspirin after acute minor stroke or transient ischemic attack increase the risk of cerebral hemorrhage?
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Humans; Ischemic Attack, Transient; Male; Middle Aged; Ti | 2014 |
[Clopidogrel resistance in cerebrovascular disease -- results of one-year follow-up].
Topics: Adult; Aged; Blood Glucose; Blood Pressure; C-Reactive Protein; Clopidogrel; Drug Resistance; Female | 2015 |
Comment: TIA response to antiplatelets stratified by glycated albumin.
Topics: Aspirin; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticlopidine | 2015 |
Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transient ischemic attack or acute minor stroke.
Topics: Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Stroke; Ticlopidi | 2015 |
Dual antiplatelet therapy for TIA reduces subsequent disability: A CHANCE to improve outcomes?
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Outcome Assessment, Health Care; Platelet | 2015 |
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A | 2015 |
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease.
Topics: Aged; Blood Glucose; Carotid Artery Diseases; Cerebral Small Vessel Diseases; Clopidogrel; Cohort St | 2015 |
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Topics: Aged; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Freq | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibit | 2016 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2017 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll | 2017 |
Risk Factors of Subacute Thrombosis After Intracranial Stenting for Symptomatic Intracranial Arterial Stenosis.
Topics: Adult; Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Female; Humans; Ischemic Attack, Transi | 2017 |
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogr | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Tic | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregat | 2017 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
[Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Comorbidity; Cross-Sectional Studies; Female; | 2008 |
Would self-expanding stent occlude middle cerebral artery perforators?
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Infarction, Middl | 2009 |
Transient ischemic attack associated with stenosis of accessory middle cerebral artery: a case report.
Topics: Aphasia; Aspirin; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; Humans; Hypertension; | 2009 |
Agenesis of the right internal carotid artery and Klippel-Feil syndrome: case report.
Topics: Abnormalities, Multiple; Brain; Carotid Artery, Internal; Female; Humans; Ischemic Attack, Transient | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
The role of transcranial Doppler embolic monitoring in the management of intracranial arterial stenosis.
Topics: Angiography, Digital Subtraction; Aspirin; Atorvastatin; Blood Flow Velocity; Cerebral Angiography; | 2011 |
Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.
Topics: Aspirin; Cerebral Revascularization; Clopidogrel; Humans; Infarction, Middle Cerebral Artery; Ischem | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol | 2010 |
Time matters for reducing risk of stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Risk; Stroke; T | 2010 |
Carotid angioplasty in asymptomatic patients undergoing CABG surgery.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Carotid Stenosis; Clopidogrel; Coronary Angiography; Cor | 2010 |
[Switching from clopidogrel hydrogen sulfate to clopidogrel besylate. Impaired antiplatelet effect in patients with ischemic stroke].
Topics: Aged; Cerebral Infarction; Clopidogrel; Drug Resistance; Humans; Ischemic Attack, Transient; Male; N | 2010 |
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A | 2010 |
Clopidogrel and burns: platelet replacement therapy may not prevent postoperative bleeding.
Topics: Aged; Burns; Clopidogrel; Epinephrine; Hemostatics; Humans; Ischemic Attack, Transient; Male; Platel | 2010 |
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Echocardiography, Transesophageal; Embolism, Paradoxi | 2011 |
TIAs - management in general practice.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Dipyridamole; Dopamine | 2010 |
Stroke and transient ischemic attack in the long-term care setting: patient characteristics, medication treatment, and length of stay.
Topics: Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Databases, Factual; Drug Administration Schedu | 2011 |
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans; | 2012 |
Medical management trumps stenting for intracranial arterial stenosis.
Topics: Angioplasty; Aspirin; Cerebral Arteries; Clopidogrel; Combined Modality Therapy; Constriction, Patho | 2011 |
My patient just had a transient ischaemic attack. Can I predict his risk for stroke? Is stroke inevitable or preventable?
Topics: Aspirin; Clopidogrel; Evidence-Based Medicine; Humans; Ischemic Attack, Transient; Middle Aged; Plat | 2011 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Combined antithrombotic treatment with aspirin and clopidogrel for patients with capsular warning syndrome: a case report.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Internal Capsule; Intracranial Thrombosis; Ischemic Atta | 2012 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; S | 2012 |
Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Fem | 2012 |
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Topics: Adolescent; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therap | 2012 |
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.
Topics: Adult; Aged; Aspirin; Clopidogrel; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Longitu | 2013 |
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emer | 2013 |
Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug | 2002 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[Dual platelet inhibition with clopidogrel and ASS. Who profits from the combination?].
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclooxygenase Inhi | 2003 |
Massive nasal bleeding and hemodynamic instability associated with clopidogrel.
Topics: Clopidogrel; Deamino Arginine Vasopressin; Epistaxis; Female; Hemodynamics; Hemostatics; Humans; Isc | 2004 |
Perioperative hemorrhage and combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Combinations; Endarterectomy, Carotid; Female; G | 2004 |
[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemo | 2004 |
[For which patient ASS, clopidogrel or dipyridamole? (interview by Dr. Med. Dirk Einecke)].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Secondary prevention of stroke with antiplatelet drugs].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, | 2004 |
Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: Yes.
Topics: Clinical Trials as Topic; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhi | 2005 |
Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No.
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inh | 2005 |
Progressive symptomatic carotid dissection treated with multiple stents.
Topics: Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Art | 2005 |
Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Ther | 2005 |
Oral clopidogrel load in aspirin-resistant capsular warning syndrome.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female | 2005 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Internal; Carotid Stenosis; Clo | 2005 |
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F | 2006 |
Enhanced platelet activation by prolactin in patients with ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Antiplatelet agents for stroke prevention following transient ischemic attack.
Topics: Angioplasty, Balloon; Aspirin; Carotid Artery Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Com | 2008 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting.
Topics: Adult; Aged; Basilar Artery; Carotid Artery, Internal; Clopidogrel; Constriction, Pathologic; Drug M | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Prescrip | 2008 |
Severe anemia associated with transient ischemic attacks involving vertebrobasilar circulation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anemia; Clopidogrel; Diagnosis, Differential; Electrocardio | 2008 |
[Transient ischemic attack associated with a calcinosis cerebri syndrome].
Topics: Aged; Brain Diseases; Calcinosis; Clopidogrel; Dysarthria; Humans; Ischemic Attack, Transient; Magne | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
[Emergency treatment of transient cerebral ischemia].
Topics: Aspirin; Clopidogrel; Emergency Treatment; Humans; Ischemic Attack, Transient; Platelet Aggregation | 2008 |
Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Platelets; Cerebrovascular Disorders; Fe | 1984 |
[Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)].
Topics: Blood Platelets; Humans; Ischemic Attack, Transient; Male; Middle Aged; Migraine Disorders; Platelet | 1980 |
[Stroke: new perspectives in prevention. Scientific symposium, 24 April 1993, Frankfurt].
Topics: Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Prog | 1993 |
Delayed neutropenia with ticlopidine.
Topics: Aged; Blood Cell Count; Female; Humans; Ischemic Attack, Transient; Neutropenia; Pneumonia; Ticlopid | 1994 |
Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Cerebral Angiography; Cerebrovascu | 1995 |
Does ticlopidine prevent reversible cerebrovascular ischemic events in women?
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Ticlopidine | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cohort Studies; Cost-Benefit Analysis; Decision Support Te | 1994 |
Ticlopidine hydrochloride and prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1993 |
Thrombotic thrombocytopenic purpura associated with ticlopidine.
Topics: Aged; Humans; Ischemic Attack, Transient; Male; Purpura, Thrombotic Thrombocytopenic; Ticlopidine | 1993 |
Ticlopidine-induced prolonged cholestasis.
Topics: Aged; Aged, 80 and over; Cholestasis; Humans; Ischemic Attack, Transient; Male; Ticlopidine | 1993 |
Phenytoin toxicity associated with ticlopidine administration.
Topics: Aged; Drug Interactions; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Male; Phenytoin; T | 1996 |
[Thrombotic thrombocytopenic purpura associated with ticlopidine].
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Ischemic Attack, Transient; Platelet Aggregation In | 1996 |
The role of antiplatelet therapy in stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Pl | 1997 |
Secondary prevention of stroke--new trials.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Dr | 1998 |
[Secondary prevention of recurrent transient ischemic attacks].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic At | 1998 |
[Lymphocytic colitis and ticlopidine].
Topics: Adrenergic alpha-Antagonists; Aged; Captopril; Colitis; Diarrhea; Female; Humans; Hypertension; Isch | 1998 |
Stent-assisted angioplasty of intracranial vertebrobasilar atherosclerosis: an initial experience.
Topics: Abciximab; Adult; Aged; Angiography; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; B | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
Ticlopidine-induced interstitial pulmonary disease: a case report.
Topics: Aged; Female; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Lung Diseases, Interstitial; | 2001 |
Fibroelastoma of the mitral valve as a cause of transient ischemic stroke.
Topics: Adult; Female; Fibroma; Heart Neoplasms; Heart Valve Diseases; Humans; Ischemic Attack, Transient; M | 2001 |
Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2001 |
Clopidogrel(TM): an alternative to acetylsalicylic acid and ticlopidine in antiplatelet therapy?
Topics: Arteriosclerosis; Canada; Cost-Benefit Analysis; Drug Evaluation; Heart Diseases; Humans; Ischemic A | 1999 |
Vascular event rates in patients with atherosclerotic cerebrovascular disease.
Topics: Age Factors; Aged; Carotid Stenosis; Cerebrovascular Disorders; Epidemiologic Methods; Humans; Intra | 1992 |
[The effects of ticlopidine and nicardipine on the prevention of symptomatic vasospasm after aneurysmal rupture].
Topics: Adult; Aged; Female; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Male; Middle Aged; N | 1988 |